Announcements Trials
Browse Landscape

Phase

Phase 3 26Phase 2 17Phase 1 4Phase NA 3Phase 4 3Phase 2/3 3Phase EARLY_PHASE1 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1Polycystic Ovary Syndrome 1

Interventions

Magnetic Resonance Spectroscopy 61Cyclophosphamide 57pembrolizumab 39fludarabine 38Radiotherapy 30Nivolumab 30Biopsy 27Metformin 23Fluorodeoxyglucose F18 22Bevacizumab 22Specimen Handling 21Temozolomide 18Cisplatin 18Radiosurgery 17Carboplatin 16Fluorouracil 15Paclitaxel 14Dexamethasone 14Radiation 13Gemcitabine 13Etoposide 13Rituximab 12Positron Emission Tomography Computed Tomography 12Letrozole 12Irinotecan 12gallium 68 PSMA-11 11durvalumab 11atezolizumab 11X-Rays 11Surgical Procedures, Operative 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Interventional × Flutamide × Clear all
NCT03507608 2025-10-16

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
25 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

NCT04597099 2023-11-02

CRM010

University of Virginia

Phase EARLY_PHASE1 Unknown
10 enrolled

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡